Abstract
The thalidomide episode was primarily responsible for strengthening or initiating leglislation and codes of practice, in many countries, on drug safety evaluation, and the environmental impact of these measures is discussed. The availability and distribution of pharmaceutical products constitute a separate issue, and are treated by reference to abuse, misuse, overdosage and the utilisation of available hospital beds.